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Supporting Figure 1. Time trends for therapy received by lung cancer patients in the United 
States. Figure based on analysis of 440,566  cases from the National Cancer Database 
diagnosed with lung cancer between 2010-2014. 
 
Supporting Figure 2. Number of persons in the United States that are eligible for Low-Dose 
Computed Tomography lung cancer screening in the United States between 2018-2040 for 
three screening policies.  
USPSTF, United States Preventive Task Force recommendations, annually screening current 
and former smokers aged 55-80 with at least a 30 pack-years smoking history that quit 
fewer than 15 years ago; CMS, the Centers for Medicare & Medicaid Services 
recommendations, annually screening current and former smokers aged 55-77 with at least 
a 30 pack-years smoking history that quit fewer than 15 years ago; Ontario, the most cost-
effective policy from a study for Cancer Care Ontario, annually screening current and former 
smokers aged 55-75 with at least a 40 pack-years smoking history that quit fewer than 10 
years ago. 
 
 
 
 
Supporting Figure 3. Census-adjusted lung cancer incidence in the United States between 
2015-2040 in the absence of Low-Dose Computed Tomography screening and for three 
screening policies implemented in 2018. 
All policies assumed 50% adherence to screening. USPSTF, United States Preventive Task 
Force recommendations, annually screening current and former smokers aged 55-80 with at 
least a 30 pack-years smoking history that quit fewer than 15 years ago; CMS, the Centers 
for Medicare & Medicaid Services recommendations, annually screening current and former 
smokers aged 55-77 with at least a 30 pack-years smoking history that quit fewer than 15 
years ago; Ontario, the most cost-effective policy from a study for Cancer Care Ontario, 
annually screening current and former smokers aged 55-75 with at least a 40 pack-years 
smoking history that quit fewer than 10 years ago.  
  
 
 
Supporting Figure 4. Census-adjusted lung cancer incidence in the United States between 
2015-2040 in the absence of Low-Dose Computed Tomography screening and for three 
screening policies implemented in 2018. 
All policies assume an adherence level of 5% in 2018, with an annual 5 percentage point 
increase until a constant adherence of 50% is reached in 2027.  
USPSTF, United States Preventive Task Force recommendations, annually screening current 
and former smokers aged 55-80 with at least a 30 pack-years smoking history that quit 
fewer than 15 years ago; CMS, the Centers for Medicare & Medicaid Services 
recommendations, annually screening current and former smokers aged 55-77 with at least 
a 30 pack-years smoking history that quit fewer than 15 years ago; Ontario, the most cost-
effective policy from a study for Cancer Care Ontario, annually screening current and former 
smokers aged 55-75 with at least a 40 pack-years smoking history that quit fewer than 10 
years ago.  
 
 
 
Supporting Figure 5. Cumulative change in demand for lung cancer therapy in the United 
States between 2015-2040 when implementing Low-Dose Computed Tomography screening 
for lung cancer in 2018, assuming that screen detected cases received stage-specific 
treatment as reported in the National Lung Screening Trial.  
Expressed as cumulative percentage change compared to no screening. All policies assumed 
constant 50% adherence to screening. USPSTF, United States Preventive Task Force 
recommendations, annually screening current and former smokers aged 55-80 with at least 
a 30 pack-years smoking history that quit fewer than 15 years ago; CMS, the Centers for 
Medicare & Medicaid Services recommendations, annually screening current and former 
smokers aged 55-77 with at least a 30 pack-years smoking history that quit fewer than 15 
years ago; Ontario, the most cost-effective policy from a study for Cancer Care Ontario, 
annually screening current and former smokers aged 55-75 with at least a 40 pack-years 
smoking history that quit fewer than 10 years ago. 
  
 
Supporting Figure 6. Absolute annual number of lung cancer patients in the United States 
requiring surgery when implementing Low-Dose Computed Tomography screening for lung 
cancer in 2018 using the Centers for Medicare & Medicaid Services criteria at different 
constant screening adherence levels. 
CMS, the Centers for Medicare & Medicaid Services recommendations, annually screening 
current and former smokers aged 55-77 with at least a 30 pack-years smoking history that 
quit fewer than 15 years ago. 
 
 
Supporting Figure 7. Absolute annual number of lung cancer patients in the United States 
requiring surgery when implementing Low-Dose Computed Tomography screening for lung 
cancer in 2018 using the Ontario criteria at different constant screening adherence levels. 
Ontario, the most cost-effective policy from a study for Cancer Care Ontario, annually screening 
current and former smokers aged 55-75 with at least a 40 pack-years smoking history that quit fewer 
than 10 years ago.  
 
 
Clinical stage  n Surgery  
(%) 
Radiotherapy 
(%) 
Chemotherapy 
(%) 
Any therapy 
(%) 
Non-small cell 
lung cancer 
 
IA 60,876 43,920 (72.1) 13,689 (22.5) 5,476 (9.0) 56,210 (92.3) 
IB 25,924 16,783 (64.7) 7,035 (27.1) 6,199 (23.9) 22,899 (88.3) 
II 30,101 16,203 (53.8) 11,658 (38.7) 15,129 (50.3) 25,680 (85.3) 
IIIA 48,808 10,538 (21.6) 31,196 (63.9) 32,757 (67.1) 39,803 (81.6) 
IIIB 26,878 1,489 (5.5) 18,499 (68.8) 19,117 (71.1) 22,253 (82.8) 
IV 182,056 5,224 (2.9) 82,756 (45.5) 91,641 (50.3) 124,814 (68.6) 
Subtotal 374,643 94,157 (25.1) 164,833 (44.0) 170,319 (45.5) 291,659 (77.8) 
Small cell lung 
cancer 
 
IA 1,571 689 (43.9) 825 (52.5) 1,108 (70.5) 1,413 (89.9) 
IB 934 199 (21.3) 565 (60.5) 683 (73.1) 795 (85.1) 
II 2,456 250 (10.2) 1,747 (71.1) 2,002 (81.5) 2,141 (87.2) 
IIIA 9,103 227 (2.5) 6,636 (72.9) 7,742 (85.0) 7,988 (87.8) 
IIIB 7,139 59 (0.8) 5,084 (71.2) 6,168 (86.4) 6,340 (88.8) 
IV 44,720 304 (0.7) 18,771 (42.0) 32,138 (71.9) 34,986 (78.2) 
Subtotal 65,923 1,728 (2.6) 33,628 (51.0) 49,841 (75.6) 53,663 (81.4) 
Overall   
Total 440,566 95885 (21.8) 198,461 (45.0) 220,160 (50.0) 345,322 (78.4) 
 
 
Supporting Table 1. Lung cancer therapy observed in the National Cancer Database by lung 
cancer type and clinical stage at diagnosis. 
Based on analysis of of 440,566  cases from the National cancer Database diagnosed with 
lung cancer between 2010-2014. For the actual analysis in the main paper, treatment 
proportions were further stratified by gender, age, stage, and histology. Patients could 
receive multiple treatments. Hence, treatment categories do not add up to 100%.  
 
 
Stage n Surgery (%) Radiotherapy (%) Chemotherapy (%) Any therapy (%) 
IA 415 388 (93.5) 26 (6.3) 28 (6.7) 407 (98.1) 
IB 104 93 (89.4) 7 (6.7) 34 (32.7) 101 (97.1) 
II 72 59 (81.9) 23 (31.9) 46 (63.9) 71 (98.6) 
IIIA 98 37 (37.8) 71 (72.4) 77 (78.6) 95 (96.9) 
IIIB 121 36 (29.8) 63 (52.1) 91 (75.2) 111 (91.7) 
IV 220 23 (10.5) 72 (32.7) 149 (67.7) 180 (81.8) 
 
Supporting Table 2. Lung cancer therapy observed in the Low-Dose-Computed Tomography 
arm of the National Lung Screening Trial by stage at diagnosis. 
Proportions were calculated based on treatment frequencies reported in Table 3 in the 
Supplementary Appendix of Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer 
mortality with low-dose computed tomographic screening. N. Engl. J. Med. 
2011;365(5):395-409.  
Patients could receive multiple treatments. Hence, treatment categories do not add up to 
100%. 
 
Policy n  Clinically detected (%) Screen detected (%) 
USPSTF 5,525,593  4,597,593 (83.3) 927,999 (16.8) 
CMS 5,495,049  4,709,017 (85.7) 786,032 (14.3) 
Ontario 5,462,657  4,908,971 (89.9) 553,686 (10.1) 
No screening 5,402,854  5,402,854 (100) - 
 
 
Supporting Table 3. Cumulative number of lung cancer cases in the United States between 
2015-2040 and the proportion of screen detected and clinically detected cases in the 
absence of Low-Dose Computed Tomography screening and for three screening policies 
implemented in 2018. 
All policies assumed constant 50% adherence to screening. USPSTF, United States 
Preventive Task Force recommendations, annually screening current and former smokers 
aged 55-80 with at least a 30 pack-years smoking history that quit fewer than 15 years ago; 
CMS, the Centers for Medicare & Medicaid Services recommendations, annually screening 
current and former smokers aged 55-77 with at least a 30 pack-years smoking history that 
quit fewer than 15 years ago; Ontario, the most cost-effective policy from a study for Cancer 
Care Ontario, annually screening current and former smokers aged 55-75 with at least a 40 
pack-years smoking history that quit fewer than 10 years ago. 
 
 
 
 
Surgery 
Scenario/ Year 2018 2023 2028 2040 
No screening 37,964 38,903 38,876 34,021 
USPSTF 74,437 (+96.1) 56,794 (+46.0) 53,781 (+38.3) 42,482 (+24.9) 
CMS 71,188 (+87.5) 54,912 (+41.2) 51,710 (+33.0) 40,719 (+19.7) 
Ontario 62,442 (+64.5) 50,632 (+30.1) 48,105 (+23.7) 38,463 (+13.1) 
 
Radiotherapy 
Scenario / Year 2018 2023 2028 2040 
No screening 81,802 84,378 85,242 81,219 
USPSTF 98,766 (+20.7) 80,426 (-4.7) 80,920 (-5.1) 78,554 (-3.3) 
CMS 96,539 (+18.0) 80,246 (-4.9) 80,677 (-5.4) 78,409 (-3.5) 
Ontario 92,377 (+12.9) 81,048 (-3.9) 81,830 (-4.0) 79,053 (-2.7) 
 
Chemotherapy 
Scenario / Year 2018 2023 2028 2040 
No screening 83,221 84,351 83,366 72,586 
USPSTF 98,776 (+18.7) 76,729 (-9.0) 75,831 (-9.0) 68,098 (-6.2) 
CMS 97,483 (+17.1) 77,192 (-8.5) 76,263 (-8.5) 68,507 (-5.6) 
Ontario 93,698 (+12.6) 78,889 (-6.5) 78,217 (-6.2) 69,603 (-4.1) 
 
Any therapy 
Scenario / Year 2018 2023 2028 2040 
No screening 141,751 146,288 147,815 137,607 
USPSTF 193,546 (+36.5) 154,914 (+5.9) 153,441 (+3.8) 140,452 (+2.1) 
CMS 188,069 (+32.7) 153,346 (+4.8) 151,635 (+2.6) 138,978 (+1.0) 
Ontario 175,527 (+23.8) 151,076 (+3.3) 150,401 (+1.7) 138,121 (+0.4) 
 
 
Supporting Table 4. Absolute annual number of lung cancer patients in the United States 
requiring surgery, radiotherapy, chemotherapy, and any therapy when implementing Low-
Dose Computed Tomography screening for lung cancer in 2018 (percentage change 
compared to no screening).All policies assumed constant 50% adherence to screening.  
USPSTF, United States Preventive Task Force recommendations, annually screening current 
and former smokers aged 55-80 with at least a 30 pack-years smoking history that quit 
fewer than 15 years ago; CMS, the Centers for Medicare & Medicaid Services 
recommendations, annually screening current and former smokers aged 55-77 with at least 
a 30 pack-years smoking history that quit fewer than 15 years ago; Ontario, the most cost-
effective policy from a study for Cancer Care Ontario, annually screening current and former 
smokers aged 55-75 with at least a 40 pack-years smoking history that quit fewer than 10 
years ago. 
 
Surgery 
Scenario/ Year 2018 2023 2028 2040 
No screening 37,964 38,903 38,876 34,021 
USPSTF 41,599 (+9.6) 53,811 (+38.3) 55,220 (+42.0) 42,334 (+24.4) 
CMS 41,248 (+8.7) 52,213 (+34.2) 52,926 (+36.1) 40,612 (+19.4) 
Ontario 40,966 (+7.9) 50,732 (+30.4) 51,160 (+31.6) 39,497 (+16.1) 
 
Radiotherapy 
Scenario / Year 2018 2023 2028 2040 
No screening 81,802 84,378 85,242 81,219 
USPSTF 83,538 (+2.1) 85,821 (+1.7) 82,811 (-2.9) 78,473 (-3.4) 
CMS 83,293 (+1.8) 85,244 (+1.0) 82,499 (-3.2) 78,391 (-3.5) 
Ontario 83,134 (+1.6) 84,862 (+0.6) 82,416 (-3.3) 78,590 (-3.2) 
 
Chemotherapy 
Scenario / Year 2018 2023 2028 2040 
No screening 83,221 84,351 83,366 72,586 
USPSTF 84,819 (+1.9) 83,872 (-0.6) 77,684 (-6.8) 68,058 (-6.2) 
CMS 84,675 (+1.7) 83,797 (-0.7) 78,153 (-6.3) 68,503 (-5.6) 
Ontario 84,560 (+1.6) 83,741 (-0.7) 78,506 (-5.8) 68,974 (-5.0) 
 
Any therapy 
Scenario / Year 2018 2023 2028 2040 
No screening 141,751 146,288 147,815 137,607 
USPSTF 146960 (+3.7) 159881 (+9.3) 157104 (+6.3) 140200 (+1.9) 
CMS 146366 (+3.3) 157940 (+8.0) 155035 (+4.9) 138840 (+0.9) 
Ontario 145931 (+2.9) 156304 (+6.8) 153622 (+3.9) 138295 (+0.5) 
 
 
Supporting Table 5. Absolute annual number of lung cancer patients in the United States 
requiring surgery, radiotherapy, chemotherapy, and any therapy when implementing Low-
Dose Computed Tomography screening for lung cancer in 2018 (percentage change 
compared to no screening). All policies assume an adherence level of 5% in 2018, with an 
annual 5 percentage point increase until a constant adherence of 50% is reached in 2027.  
USPSTF, United States Preventive Task Force recommendations, annually screening current 
and former smokers aged 55-80 with at least a 30 pack-years smoking history that quit 
fewer than 15 years ago; CMS, the Centers for Medicare & Medicaid Services 
recommendations, annually screening current and former smokers aged 55-77 with at least 
a 30 pack-years smoking history that quit fewer than 15 years ago; Ontario, the most cost-
effective policy from a study for Cancer Care Ontario, annually screening current and former 
smokers aged 55-75 with at least a 40 pack-years smoking history that quit fewer than 10 
years ago. 
 
